Microbot Medical Inc. (MBOT) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Microbot Medical Inc. (NASDAQ: MBOT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.09 (-2.68% 1D, market cap $75.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MBOT ranks #508 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), MBOT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.8%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and LNSR (LENSAR Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M). Among the 5-stock peer group, MBOT leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
Per MBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883975), Microbot Medical Inc. generated $0 in revenue, -$13.1M in net income, and -$13.1M in free cash flow against $81.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 48.5 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While MBOT currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.25) and Max Pain ($1.14) forces dealer call-delta covering toward $3.00.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Microbot Medical Inc. (MBOT) dropped -2.68% to $1.09, trading at 8% of its 52-week range ($0.93 – $2.86). Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. The Company believes the OBLs represent a rapidly growing healthcare
Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, today announced that ELMNT IR, a multisite outpatient interventional radiology practice in
Opportunity to Connect with Hospital Administrators and Physicians to Foster Expanded Adoption of the LIBERTY SystemHINGHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and di
Citizens analyst Daniel Stauder initiates coverage on Microbot Medical (NASDAQ:MBOT) with a Market Outperform rating and announces Price Target of $2.5.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:MBOT) with a Buy and maintains $12 price target.
The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets. HINGHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Microbot Medic
The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international markets.HINGHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Microbot
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MBOT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MBOT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Microbot Medical Inc. (MBOT) ranks #508 by composite RQD confidence (41/100, grade D-) and #696 by equity capitalization ($75.2M). Within this direct 5-issuer industry benchmark cohort, MBOT leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DAVI currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MBOT at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MBOT
ACTIVE
Microbot Medical Inc. | D- | 41/100 | — | — | -15.8% | -2.68% | $75.2M | Benchmark Subject |
| QTEX QTREX Quantum Ltd. | E | 31/100 | — | 0.7% | -35.0% | -7.58% | $73.9M | /qtex-vs-mbot → |
| LNSR LENSAR Inc. | E | 24/100 | — | 39.4% | -35.0% | -2.18% | $73.3M | /lnsr-vs-mbot → |
| DAVI Davion Healthcare Plc | D | 47/100 | — | — | — | -37.55% | $67.3M | /davi-vs-mbot → |
| SKIN SkinHealth Systems Inc. (Class A) | D- | 36/100 | — | 65.3% | -26.9% | -2.07% | $66.0M | /skin-vs-mbot → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Microbot Medical Inc. (MBOT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.1M, operating cash flow of -$13.0M, and free cash flow of -$13.1M (-48.1% YoY). On the balance sheet, MBOT closed FY2025 with $81.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$13.1M | -$13.0M | -$13.1M | $81.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$11.4M | -$8.8M | -$8.9M | $6.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$10.7M | -$8.5M | -$8.5M | — | — |
As of 2026-11-02, Microbot Medical Inc. (NASDAQ: MBOT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.09 (-2.68% 1D, market cap $75.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MBOT ranks #508 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), MBOT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.8%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and LNSR (LENSAR Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M). Among the 5-stock peer group, MBOT leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
Per MBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883975), Microbot Medical Inc. generated $0 in revenue, -$13.1M in net income, and -$13.1M in free cash flow against $81.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MBOT last traded at $1.09 (-2.68% on volume of 1,334,965 shares), positioning the stock -12.80% below its 50-day simple moving average ($1.25) and -41.08% below its 200-day simple moving average ($1.85). Across its 52-week range of $0.93 to $2.86, MBOT sits at the 8.3% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.23).
Why MBOT Stock dropped -2.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).